Replies to post #731 on Biostax Corp (BTAX)

[SSDBase]

Right, I didn't mention that PR claim of future revenue.

I also didn't mention the previous Nigerian revenue PR they put out in November, 2012. A few quotes from that gem.
http://www.tnibiotech.com/investor-relations/press-releases/142-tni-biotech-inc-signs-exclusive-distributor-agreement-for-federal-republic-of-nigeria-with-g-ex-technologies-st-maris-pharma-gb-pharma-holdings-llc

G-Ex Technologies/St. Maris Pharma, as part of the agreement, will provide TNIB with a revolving letter of credit for the minimum purchase of 750,000 doses monthly of IRT-103 LDN or IRT-104 LDN cream beginning March 1, 2013 priced at $1.00 dollar per dose.

The agreements calls for G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC to purchase a minimum of 15,000,000 doses monthly within 24 months to maintain their exclusive agreement. Once G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC reach sales of 1,000,000 million doses per day TNIB has agreed to joint venture a factory in the Federal Republic of Nigeria to meet local demands.

Noreen Griffin, CEO of TNI BioTech, Inc. said "this contract shows TNI BioTech's commitment to generate revenue during our first year of operations."

I did a full review of that wonderful deal last year.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=81656453

Needless to say, I am not surprised it produced nothing. I am surprised people still are still falling for this nonsense.

I will take a more detailed look at the AHAR deal and see if they were any better at covering their tracks this time.